This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Dermatitis JAK Inhibitor NDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of Pfizer's (PFE) candidate abrocitinib in atopic dermatitis by three months.
Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of Lilly (LLY)/Incyte's (INCY) label expansion application for Olumiant in atopic dermatitis by three months.
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD
by Zacks Equity Research
The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.
Biotech Stock Roundup: BLUE/BMY's CAR T Therapy Nod, KLDO's COVID-19 Study News & More
by Zacks Equity Research
The biotech sector gains prominence with new product approvals from bluebird (BLUE)/Bristol Myers Squibb (BMY) and other coronavirus updates.
Incyte (INCY) Gets EU Nod for Cholangiocarcinoma Drug Pemazyre
by Zacks Equity Research
The European Commission approves Incyte's (INCY) Pemazyre (pemigatinib) for the treatment of locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.
Lilly/Vir's Cocktail COVID-19 Therapy Meets Study Endpoint
by Zacks Equity Research
Eli Lilly (LLY), Vir Biotechnology and Glaxo are developing a combination of their respective monoclonal antibodies as a potential treatment for mild-to-moderate COVID-19 patients.
Biotech Stock Roundup: REGN Cocktail Data Positive, INCY's Jakafi Disappoints & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Regeneron (REGN) and Incyte (INCY).
Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk
by Zacks Equity Research
Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.
Lilly (LLY) COVID-19 Antibody Combo Cuts Death/Hospitalization
by Zacks Equity Research
Lilly's (LLY) combination of its antibody drugs, bamlanivimab and etesevimab cuts death and hospitalizations, per new data from the BLAZE-1 phase III study.
Lilly (LLY) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its antibodies to treat COVID-19 and pipeline.
Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod
by Zacks Equity Research
CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).
The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte
Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates
by Zacks Equity Research
Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.
Bristol Myers (BMY) Gets European Commission Nod for Inrebic
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.
Incyte (INCY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 13.41% and 17.87%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.
Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody
by Zacks Equity Research
Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.
Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib
by Zacks Equity Research
Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.
Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales
by Zacks Equity Research
Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.
Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook
by Zacks Equity Research
Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.
Lilly's (LLY) Bamlanivimab Combo Lowers COVID-19 Hospitalization
by Zacks Equity Research
Eli Lilly's (LLY) combination of its COVID-19 antibodies bamlanivimab (LY-CoV555) plus etesevimab (LY-CoV016) reduces COVID-19-related hospitalizations and deaths by 70%.